TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06667505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choice-ICD
Description: The eHealth intervention theoretically driven, interactive and provides personalised information to patients and family members when and where they wish to access it. Five short (2-3 minutes) videos, involving patients, caregivers and professionals, are uploaded onto the APP, alongside animation clips and useful links to online resources. A discussion forum will be accessible for participants using the APP, which will be closely moderated by the researcher, who will ensure any concerning posts or dialogue are promptly removed, and the necessary action is taken. The diary function will allow patients to record and be reminded of future appointments. Patients and family members will engage with the intervention for 3 months.
Study: NCT06663371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Physical Fitness
Description: The single module training paradigm followed a circuit-style format, with each training module consisting of 6 to 8 distinct exercise movements. Taking the INT training intervention on Mondays as an example, the training protocol involved completing one major module (e.g., plyometric exercises) before transitioning to another module (e.g., core stability exercises). Specific exercise methods, such as box jumps, were performed until all sets were completed before moving on to the next exercise (e.g., continuous depth jumps).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Physical Training
Description: In the fundamental strength training, a circuit training modality is employed, with each training segment comprising 5 to 7 exercise movements. For instance, a series of squat exercises is performed initially, followed by upper body strength training such as bench presses; each movement must be completed with the specified number of sets and repetitions before proceeding to the next exercise. Explosiveness training enhances the rapid contraction capabilities of the muscles through a series of jumping and throwing movements, while flexibility exercises improve the range of motion of muscles and joints through a combination of static and dynamic stretching.
Study: NCT06667440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Women in the intervention group will apply cryotherapy on their hypogastrium with a coldpack
Study: NCT06672276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3606
Description: TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.
Study: NCT06671691

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT level I
Description: 20Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT level II
Description: 23Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT level III
Description: 26Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT level IV
Description: 28Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT level V
Description: 30Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
Study: NCT06673004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian tissue allo-transplantation
Description: Participants will receive donor ovarian tissue with immunosuppression
Study: NCT06672913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: skin to skin contact care
Description: Early and regular skin to skin contact in NICU GA: \< 28 weeks: After the 72nd hour GA: 28 - 32 weeks: As soon as stabilization is ensured
Study: NCT05152446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion management scheme
Description: * To set up a pediatric intravenous infusion team;~* To form standardized procedures by carrying out a quality improvement program in collecting and sending samples for inspection once suspected CLABSI occurs (1 month for training and 3 months for continuous improvement ); providing infusion training curriculums to nurses in forms of lectures, group discussions, operation demonstrations, and scenario simulations, holding practice review meeting with them; providing elements to caregivers of educational leaflet, nurse-provided education during patients' infusion therapy( 6-month implementation);~* To observe the continued daily infusion practice in 6 months.
Study: NCT06671912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Given PO
Study: NCT06058845

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tamarindus indica fruit juice_A
Description: The participants will be exposed to 10% Tamarind pulp juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tamarindus indica fruit juice_B
Description: The participants will be exposed to 30% Tamarind pulp juice
Study: NCT05683561

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: D0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: D0; intramuscular injection
Study: NCT04491422

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Next Steps Counseling with Real-Time Drug Level Feedback
Description: Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
Study: NCT06671912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Given PO
Study: NCT04976179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose to be given as an intravenous infusion
Study: NCT06671912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Given PO
Study: NCT04976179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Ferrous sulphate tablet to be taken orally
Study: NCT06671912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammogram
Description: Undergo mammogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammogram
Description: Undergo mammogram

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06672523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986504
Description: Specified dose on specified days
Study: NCT04998526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The cold gel pack will be applied to the nape.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The gel pack kept at room temperature will be applied to the nape.
Study: NCT04879927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resource Matching
Description: Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
Study: NCT06258473

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: Training and support on Simple app for HTN/DM patient management \& training NCD corner clinicians on clinical guidelines of Upazila Health complex
Study: NCT05565417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMT-009
Description: Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMT-009
Description: Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMT-009
Description: Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).
Study: NCT05896579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training will include supervised high-intensity interval training for \~35 minutes 3x/week on an upright stationary bicycle and unsupervised continuous aerobic exercise for \~30 minutes 2x/week.
Study: NCT05774392

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT04726098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone high dose
Description: High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone low dose
Description: Low doses: dexamethasone 6 mg/day 10 days.
Study: NCT06672523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BMS-986504
Description: Specified dose on specified days
Study: NCT06672302

Intervention type: DIAGNOSTIC_TEST
Intervention: ExoPred
Description: Performing in vitro diagnostics with devices developed by EXoPERT

Intervention type: DIAGNOSTIC_TEST
Intervention: ExoPred
Description: Performing in vitro diagnostics with devices developed by EXoPERT
Study: NCT06671860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Individuals were randomly assigned to the REP (Routine Exercise Program) group and the OHP group. The REP group received the traditional exercise protocol and the OHP group received oculomotor exercises and myofascial release techniques in addition to the traditional exercise. The groups were evaluated before the treatment and at the end of the 6-week treatment sessions. Patient education was given to the patients before both programs. Patient education included information about nonspecific chronic neck pain, symptoms, and complications, as well as assessment methods, parameters, tests, and exercises.~The first group, the REP group (n=19), received routine exercises, and the second group, the OHP group (n=19), received oculomotor exercises and myofascial relaxation techniques in addition to the routine exercise program. The treatments were applied for six weeks, three sessions per week, under the supervision and guidance of a physiotherapist in the clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individuals were randomly assigned to the REP (Routine Exercise Program) group and the OHP group. The REP group received the traditional exercise protocol and the OHP group received oculomotor exercises and myofascial release techniques in addition to the traditional exercise. The groups were evaluated before the treatment and at the end of the 6-week treatment sessions. Patient education was given to the patients before both programs. Patient education included information about nonspecific chronic neck pain, symptoms, and complications, as well as assessment methods, parameters, tests, and exercises.~The first group, the REP group (n=19), received routine exercises, and the second group, the OHP group (n=19), received oculomotor exercises and myofascial relaxation techniques in addition to the routine exercise program. The treatments were applied for six weeks, three sessions per week, under the supervision and guidance of a physiotherapist in the clinic.
Study: NCT06672159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two defibrillators
Description: DSED procedure consists of pads placed in anterior-lateral position, and in anterior-posterior position. Defibrillations will be given in rapid sequence, less than a second apart. All other aspects of resuscitation in accordance to existing guidelines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One defibrillator
Description: Standard OHCA treatment according to existing guidelines.
Study: NCT04571762

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT (a fraction dose adapted to the OAR geometry-of-the-day, 5 fractions) performed on the MR-Linac
Study: NCT04746547

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir 50 MG
Description: Twice daily dolutegravir with rifampicin containing TB treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir 10 MG
Description: Twice daily dolutegravir with rifampicin containing TB treatment
Study: NCT04872985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg orally once per day. Pyrotinib starts with a dose of 240 mg once daily for one week, followed by 320 mg once daily for the next week, before transitioning to 400 mg once daily as maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2,q3W\*4
Study: NCT06562374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency Ultrasound Therapy
Description: The ultrasound will be delivered at a frequency of 33 kHz at power levels of 4-10 Pascals with a program of 1.6 seconds on and 1.6 seconds off. The generators will be encased in epoxy within the Osteoarthritis baths. The intervention will be repeated on every second or third day to allow time for healing
Study: NCT04872985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: 100 mg/m2,q3W\*4
Study: NCT05770388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: App Take Care of Your Mood
Description: The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App Take Care of Your Mood
Description: The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder messages and counseling
Description: Participants receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary.
Study: NCT05578443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10g Astragalus
Description: Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20g Astragalus
Description: Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
Study: NCT04724616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program (CARTOON)
Description: CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
Study: NCT05837832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk-based phospholipids
Description: Powder based, fat-rich fraction of whey dissolved in water. Contains lactose.
Study: NCT06354023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Description: All participants will receive six weeks of treatment. Once per week, they will receive one intra-articular injection of 2cc (15IU) recombinant human growth hormone in their affected knee. The injection will also contain 1cc (1%) Lidocaine and 1cc (0.5%) Marcaine and Epinephrine for anesthetic purposes. The participants will receive a total of 6 growth hormone injections.
Study: NCT06376500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS with cognitive training programme
Description: Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes and it is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS with cognitive training programme
Description: Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes and it is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
Study: NCT06201234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib + Elacestrant
Description: Olaparib 600 mg orally daily and elacestrant 400 mg orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib 600 mg orally daily
Study: NCT04872985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 30mg/m2, q3w\*4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 30mg/m2, q3w\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, q3w\*4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, q3w\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2, q3w\*4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 100 mg/m2, q3w\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 120mg/m2 qw\*12 or 260mg/m2 q3w\*4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab paclitaxel
Description: 120mg/m2 qw\*12 or 260mg/m2 q3w\*4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg orally once per day
Study: NCT06263166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress ball intervention
Description: Women should squeeze and loosen the stress ball given to them during the vaginal examination and continue this process until the examination is completed.
Study: NCT05200351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine assisted Therapy (EAT)
Description: 15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
Study: NCT05105243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist